GDF-11 (Growth Differentiation Factor 11)
Also known as: GDF11, Bone Morphogenetic Protein 11, BMP-11, young blood factor
GDF-11 is a research compound with significant controversy around dose, effect, and safety. Research use only.
Overview
TGF-β superfamily member proposed as a 'young blood factor' — circulating GDF-11 declines with age, and young plasma transfusion in parabiosis experiments reversed aging phenotypes in mice. A high-profile but contested research area: some studies show rejuvenating effects in heart, muscle, and brain; others using purified recombinant GDF-11 show cardiac hypertrophy and muscle wasting at pharmacologic doses.
Research Summary
The 2013–2014 parabiosis studies from Amy Wagers' lab at Harvard proposed GDF-11 as the primary rejuvenating factor in young blood. However, subsequent work by Lee and others showed that purified recombinant GDF-11 at pharmacologic doses caused cardiac hypertrophy, muscle atrophy, and weight loss — opposite of the proposed rejuvenating effects. The field now views GDF-11 as highly dose-sensitive with a narrow therapeutic window, if one exists at all.
Dosing Range
low
0.1mg/kg
moderate
0.3mg/kg
high
1mg/kg
Units: mg/kg · Frequency: every 3–7 days (SC); research protocols vary widely
Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.
Administration Routes
Reconstitution Notes
Recombinant protein requiring careful reconstitution in sterile PBS or manufacturer-supplied buffer. Store at -80°C; avoid freeze-thaw cycles. Carrier protein (0.1% BSA) recommended to prevent adsorption to container surfaces. Do not vortex.Step-by-step reconstitution guide →
Supplies you'll need
Affiliate links — Research Stack may earn a small commission at no extra cost to you.
Reported Side Effects
- Cardiac hypertrophy (at pharmacologic doses — the key safety concern)
- Muscle wasting and weight loss
- Reproductive effects (GDF-11 inhibits spermatogenesis and folliculogenesis)
- Cachexia-like syndrome at high doses
- Neurological effects (dose-dependent)
Research Papers
2 peer-reviewed sourcesCommunity Experiences
Aggregated from public forums. Anecdotal — not clinical evidence.
Longevity community debate on GDF-11 research controversy and whether young plasma benefits are attributable to GDF-11.
View original threadResearch discussion on GDF-11 with focus on the contradictory literature and safety concerns.
View original threadOverview
GDF-11 (Growth Differentiation Factor 11) is a member of the TGF-β superfamily that attracted enormous scientific attention in 2013–2014 when Harvard researchers proposed it as the primary rejuvenating factor in young blood. The parabiosis experiments — surgically joining old and young mice to share circulation — had shown that aged mice gained measurable improvements in cardiac, skeletal muscle, and neurological function. GDF-11 was identified as the causative factor via mass spectrometry of young vs. old blood.
The story became more complicated quickly. This remains one of the most actively contested areas in aging biology.
Mechanism
TGF-β Superfamily Signaling
GDF-11 binds ActRIIB and ALK4/5 receptors, activating the canonical SMAD2/3 pathway:
- GDF-11 binds ActRIIB (type II receptor) → recruits ALK4 or ALK5 (type I receptor)
- Type I receptor kinase phosphorylates SMAD2 and SMAD3
- SMAD2/3-SMAD4 complex enters nucleus
- Gene transcription changes affecting cell differentiation, proliferation, and function
Proposed Rejuvenating Mechanism (Wagers et al., 2013–2014)
- GDF-11 levels high in young blood → decline with age
- Young blood infusion into old mice restored GDF-11 → activated SMAD2/3 in cardiac and skeletal muscle
- Cardiac hypertrophy reversed; muscle regeneration improved; neurogenesis stimulated
- Key paper: 2014 Cell paper (PMID 24404486) showing 0.1mg/kg GDF-11 IV over 30 days reversed cardiac aging markers
The Controversy (Lee et al., 2015)
- Lee (Harvard) and colleagues used different detection methods and found GDF-11 does not decline with age in mice — and is nearly identical to circulating myostatin (GDF-8)
- Recombinant GDF-11 at 0.1–1mg/kg caused weight loss, muscle wasting, and cardiac hypertrophy in aged mice
- Proposed: the original studies may have misidentified GDF-8/myostatin as GDF-11 due to antibody cross-reactivity
Current Scientific Consensus
The field remains divided. Most researchers agree:
- GDF-11 has important developmental roles (establishing anterior-posterior body axis in embryos)
- The rejuvenating effects of young blood are real but multi-factorial
- GDF-11's contribution, if any, requires very precise physiologic dosing
- Pharmacologic (supraphysiologic) doses are clearly catabolic and cardiotoxic
Research Implications
This controversy illustrates critical issues in aging biology: the importance of measurement method specificity (immunoassay vs. mass spectrometry), dose-response complexity in TGF-β biology, and the danger of extrapolating from parabiosis (which changes hundreds of circulating factors simultaneously) to single-molecule conclusions.
Related Anti-aging Peptides
AHK-Cu (Alanine-Histidine-Lysine Copper)
Anti-AgingAHK copper peptide · Ala-His-Lys copper
Copper-chelating tripeptide structurally related to GHK-Cu but optimized for scalp and hair follicle applications. AHK-C…
Carnosine
Anti-Agingβ-alanyl-L-histidine · L-carnosine
Naturally occurring dipeptide (β-alanine + L-histidine) found at high concentrations in skeletal muscle and brain. Funct…
Epithalon
Anti-AgingEpitalon · Epithalone
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from Epithalamin, a polypeptide extract of the pineal gl…